EGFR-TKI The personalized anti-cancer agent screening system and process for EGFR-TKI resistant patients using the circulating tumor cells derived on patients with the lung cancer

摘要

The present invention relates to a personalized anti-cancer agent screening system and method for epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) resistant patients using circulating tumor cells (CTCs) of patients with lung cancer and, more specifically, to a system and a method for screening a personalized anti-cancer agent among various candidate anti-cancer agents through an anti-cancer agent reaction test after separating CTCs from the blood of EGFR-TKI resistant patients using a rare cell separator.